Remedium Capital Partners, LLC
WEST PALM BEACH, FL · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$273.6M2026 Q3
Positions6
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%
Top Holdings
SYRE
Spyre Therapeutics
37.8%
ORKA
Oruka Therapeutics
29.0%
DMRA
Damora Therapeutics
15.9%
JBIO
Jade Biosciences
9.3%
KRSA
Korsana Biosciences
6.1%
CBIO
Crescent Biopharma
1.9%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.